Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We maintain our Neutral recommendation for Greatbatch Inc. (GB - Analyst Report). Revenues and earnings for first-quarter fiscal 2011 topped the Zacks Consensus Estimates, buoyed by solid double-digit growth across the company’s Vascular Access, Orthopedic and Electrochem franchises.

The company’s Vascular business (sales climbed 28% in the quarter) is benefiting from higher introducer sales and favorable ordering trends while a rebounding orthopedic market is contributing to growth in its Orthopedic (up 34%) franchise.

Moreover, Greatbatch’s Electrochem business, which had struggled in fourth-quarter 2010, had a strong turnaround in the first quarter, helped by customer inventory rebuilds.

However, the healthy results were partly ebbed by a still weak CRM business. The sluggish revenue growth (up 1%) in this business in the first quarter reflects sustained pricing pressure and general softness in the market.

Greatbatch has generated solid operating cash flows in the first quarter. The company expects to continue using cash flows to deleverage its balance sheet and meet R&D requirements.

Greatbatch is a leading producer and supplier of batteries, capacitors and components used in implantable medical devices. The company has been acquiring complementary businesses over the last few years to boost sales. Moreover, Greatbatch’s pipeline is healthy with a number of products currently in development that are expected to support growth in the long run.

The company, in 2010, extended its tie-up with St. Jude Medical (STJ - Analyst Report), which has provided it an exclusive supplier status of filtered feedthroughs (used in CRM devices) through 2017. Moreover, Greatbatch, in February 2011, inked a five-year deal with Boston Scientific (BSX - Analyst Report).                                

We feel that improving trends across the orthopedic and vascular markets should boost operating results moving forward, supported by a resurgent Electrochem business. Moreover, synergies from cost-cutting and restructuring initiatives are expected to support margin expansion.

However, a soft CRM market may prove to be challenging for the company in 2011. We are also cognizant of the pricing headwind.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.61 +6.34%
RAMBUS INC RMBS 12.38 +5.00%
NETFLIX INC NFLX 347.87 +4.97%
BOFL HOLDING BOFI 85.27 +4.93%
E COMMERCE C DANG 12.59 +4.22%